174 patents
Page 5 of 9
Utility
Co-administration of a Hyaluronidase and ANTI-C5 Antibody for Treatment of Complement-associated Conditions
16 Dec 21
Provided herein are compositions and methods for treating a human patient with a complement-associated condition (e.g., PNH or aHUS) by subcutaneously co-administering to the patient a hyaluronidase (e.g., rHuPH20) and an anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).
Andrew Denker, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Yang Dai, Xiang Gao
Filed: 30 Oct 19
Utility
Monovalent anti-properdin antibodies and antibody fragments
14 Dec 21
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin.
Douglas L. Sheridan, Paul P. Tamburini, Taneisha Ann-Tanara Mack, Walter C. Voegtli
Filed: 30 Jan 18
Utility
Inhibition of Tissue Factor Pathway Inhibitor with Factor Xa Derivatives
9 Dec 21
The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley
Filed: 16 Feb 21
Utility
Antidotes to Factor Xa Inhibitors
2 Dec 21
The present disclosure relates to antidotes to anticoagulants targeting factor Xa.
Pamela B. Conley, Genmin Lu, Leonard G. Presta, John T. Curnutte
Filed: 18 Jun 19
Utility
Treating muscle weakness with alkaline phosphatases
30 Nov 21
The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.
Andre Marozsan
Filed: 31 Mar 17
Utility
Preparation of Factor Xa Derivatives
11 Nov 21
The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product.
Mark Karbarz, Pamela B. Conley, Genmin Lu
Filed: 9 Mar 21
Utility
Antidotes for Factor Xa Inhibitors and Methods of Using the Same
4 Nov 21
The present invention relates antidotes to anticoagulants targeting factor Xa.
Uma Sinha, Genmin Lu, Pamela B. Conley
Filed: 9 Mar 21
Utility
DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
28 Oct 21
Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof, in pediatric patients.
Lori PAYTON, Andrew DENKER, Eugene Scott SWENSON, Rajendra PRADHAN, Stephan ORTIZ, Marc VALLEE, Christian MIX, Xiang GAO
Filed: 29 May 19
Utility
Method of purifying a heterologous protein from an egg white
26 Oct 21
The present invention is related a method of purifying a heterologous protein from an egg white.
Liang Chen, Markley C. Leavitt, Michael Titus, Stephen Palmieri
Filed: 22 Aug 17
Utility
Manufacturing of Glycoproteins
14 Oct 21
A method of producing recombinant alkaline phosphatase comprising control of production parameters, particularly harvest clarified culture fluid (HCCF) and filtration pool (UFDF), to provide a defined total sialic acid content.
Rahul GODAWAT, Meghan DEWITT, Siguang SUI, Saravanamoorthy RAJENDRAN
Filed: 13 Mar 19
Utility
Lyophilized Formulations for Factor Xa Antidote
16 Sep 21
The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes.
Juan Wang, Gregory A. Sacha, Phuong M. Nguyen
Filed: 28 May 21
Utility
Atypical Hemolytic Uremic Syndrome (Ahus) Biomarker Proteins
16 Sep 21
The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor.
Susan Faas MCKNIGHT, Roxanne COFIELL, Anjli KUKREJA, Krystin A. BEDARD, Yan YAN
Filed: 29 Jan 21
Utility
Methods for treating tracheobronchomalacia
14 Sep 21
The disclosure features methods for treating tracheobronchomalacia (TBM) in a patient having hypophosphatasia (HPP), such as an infant, by administering a soluble alkaline phosphatase (sALP) to the patient.
Howard M. Saal
Filed: 18 Aug 17
Utility
Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders
7 Sep 21
The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood.
Mayur Movalia, Andrea Illingworth, Susan Faas McKnight, Russell P. Rother
Filed: 9 Oct 18
Utility
Method for simultaneous quantification of ALXN1210 and eculizumab in human serum or urine
7 Sep 21
Provided herein are methods for simultaneously detecting and quantifying antibodies which bind to the same target and have high sequence identity, such as eculizumab and ALXN1210, present together or alone in a biological sample.
Meng Chen, Ryan Pelto
Filed: 28 Mar 18
Utility
Methods of replicating a large scale eculizumab production cell culture
31 Aug 21
Provided herein are methods of replicating a large scale eculizumab production cell culture in a small scale culture.
Hunter F. Malanson, Pratik Jaluria
Filed: 10 Dec 19
Utility
Antibody Immune Cell Inhibitor Fusion Proteins
26 Aug 21
The disclosure provides antibody immune cell inhibitor fusion proteins comprising four polypeptide chains that form two antigen binding sites and at least two immune cell receptor binding sites that inhibit or diminish activation of an immune effector cell when bound to a target antigen.
Julian Chandler
Filed: 23 Apr 18
Utility
Methods for Treatment of Refractory Generalized Myasthenia Gravis
12 Aug 21
The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5).
Camille Bedrosian, Fanny O'Brien, Jing Jing Wang
Filed: 15 Jan 21
Utility
Humanized ANTI-CD200 Antibodies and Uses Thereof
29 Jul 21
Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200.
Taneisha Ann-Tanara MACK, Douglas L. SHERIDAN, Tadas PANAVAS
Filed: 20 Dec 18
Utility
Methods for treating hypophosphatasia in children
20 Jul 21
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.
Kenji Fujita, Dawn Phillips
Filed: 1 Sep 16